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Abstract
Background: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality and severe maternal
morbidity. The Non-pneumatic Anti-Shock Garment (NASG), a first-aid lower-body compression device, may
decrease adverse outcomes from obstetric hemorrhage. This article is the first to report the effect of the NASG for
PPH.
Methods: This pre-intervention/NASG study of 854 women was conducted in four referral facilities in Nigeria and
two in Egypt between 2004-2008. Entry criteria were women with PPH due to uterine atony, retained placenta,
ruptured uterus, vaginal or cervical lacerations or placenta accreta with estimated blood loss of ≥ 750 mL and one
clinical sign of shock. Differences in demographics, conditions on study entry, treatment and outcomes were
examined. The Wilcoxon rank-sum test and relative risks with 95% confidence intervals were calculated for primary
outcomes - measured blood loss, emergency hysterectomy, mortality, morbidity (each individually), and a
combined variable, “adverse outcomes”, defined as severe morbidity and mortality. A multiple logistic regression
model was fitted to test the independent association between the NASG and the combined severe morbidity and
mortality outcome.
Results: Measured blood loss decreased by 50% between phases; women experienced 400 mL of median blood
loss after study entry in the pre-intervention and 200 mL in the NASG phase (p < 0.0001). As individual outcomes,
mortality decreased from 9% pre-intervention to 3.1% in the NASG phase (RR 0.35, 95% CI 0.19-0.62); severe
morbidity decreased from 4.2% to 1%, in the NASG phase (RR 0.24, 95% CI 0.09-0.67). As a combination, “adverse
outcomes,” decreased from 12.8% to 4.1% in the NASG phase (RR 0.32, 95% CI 0.19-0.53). In a multiple logistic
regression model, the NASG was associated with the combined outcome of severe maternal morbidity and
mortality (OR 0.42, 95% CI 0.18-0.99).
Conclusion: In this non-randomized study, in which bias is inherent, the NASG showed promise for reducing
blood loss, emergency hysterectomy, morbidity and mortality associated with PPH in referral facilities in Egypt and
Nigeria.
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Postpartum hemorrhage (PPH) is the single largest
cause of maternal death worldwide. These deaths are
largely preventable with skilled attendance and compre-
hensive emergency obstetric care. While the majority of
maternal deaths from hemorrhage occur in low-resource
settings, PPH-related mortality and morbidity are rising
in higher-resource countries as well [1]. Developing
improved strategies for managing PPH is essential to
reducing these unnecessary deaths.
A woman suffering from PPH can die within 2 hours
unless she receives immediate and appropriate medical
care [2]. The identification of complications and the
decision to take a woman to a health facility may be
delayed and transportation may not be available. When
a woman suffering from PPH arrives at a health facility,
there may not be trained staff, essential supplies or
medications available to treat her [3].
Uterine atony makes up the largest single etiology
comprising PPH, and can be reduced by 50% with the
performance of Active Management of Third Stage
Labor (AMTSL) [4]. However, even with AMTSL, PPH
from uterine atony can occur. Other etiologies of PPH,
which are not prevented by AMTSL include retained
placenta, ruptured uterus, vaginal/cervical lacerations
and placenta accreta. These non-atonic PPH etiologies
are not affected by the administration of uterotonics,
and almost always require surgery. Current treatment
protocols for PPH and hypovolemic shock include the
administration of treatment uterotonics, bimanual mas-
sage, manual removal of the placenta, repair of lacera-
tions, blood transfusion and surgery. All of these may be
unobtainable in low-resource settings, except at tertiary
facilities, and women may experience long delays receiv-
ing treatment even at these facilities [5].
When delays in management of PPH occur, first-aid is
needed to resuscitate and stabilize women with hypovo-
lemic shock until definitive treatment is obtained. The
Non-pneumatic Anti-Shock Garment (NASG) is a first-
aid, lower-body compression device made from neo-
prene and Velcro™ (Zoex Corporation, Ashland, OR,
USA). Each of its nine segments is sequentially wrapped
tightly around a hemorrhaging woman’s legs, pelvis and
abdomen (Figure 1). The abdominal segment applies
extra compression with a small foam ball. The circum-
ferential counter pressure applied by the NASG reduces
the total vascular space in the lower portion of the body
while simultaneously increasing the volume of blood in
the central circulation. Thus, oxygenated blood is
shunted to the vital organs [6]. The application of the
NASG reverses hemorrhagic shock and can stabilize a
patient while awaiting transport, during transport, or
during delays in receiving care at referral facilities.
T h eN A S Gi su n i q u e l ys u i t e df o ru s ei nl o w - r e s o u r c e
countries due to its simple design and relatively low
cost. Currently, the device costs $170 USD and training
for application is relatively brief. After decontamination
and laundering, the device can be re-used up to 40
times. Vaginal procedures are performed with the
NASG in place and abdominal surgeries can be con-
ducted by opening the abdominal section during
surgery.
Published papers have reported the utility of the
NASG for women with obstetric hemorrhage from all
etiologies in low-resource referral facilities [7-11]. In
this article, we examine the outcomes of the NASG on
women experiencing PPH at two such facilities in Egypt
and four in Nigeria. This sub-set of data on PPH etiolo-
gies has never before been explored, as PPH is the lead-
ing cause of obstetric hemorrhage, we feel it worthy of a
separate analysis.
Methods
This study is a sub-analysis of data collected between
2004 and 2008. The methods have been described in
more detail in previously published studies of obstetric
hemorrhage from all etiologies [11,12]. Briefly, this is a
pre-intervention/intervention study, data were collected
during the pre-intervention phase, when clinicians used
a standardized obstetric hemorrhage protocol, for
women with hypovolemic shock secondary to obstetric
hemorrhage and outcomes of interest were recorded.
Next, the NASG was introduced. During the NASG
intervention phase, clinicians used the same protocol
plus the NASG for women with hypovolemic shock sec-
ondary to obstetric hemorrhage. The pre-intervention
and intervention phases were exactly the same length in
the Egypt study, length of pre-intervention and interven-
tion phases in Nigeria differed, but in each of the four
facilities pre-intervention phases were shorter than
intervention phases.
For the present PPH sub-set analysis, we examined
only the data on women admitted for PPH (n = 854) at
tertiary care facilities with roughly equivalent pre-inter-
vention (n = 343) and NASG phases (n = 511). PPH
diagnoses included uterine atony, retained placenta or
tissue, ruptured uterus, vaginal/cervical lacerations and
placenta accreta. To be eligible for the study, women
presented with PPH and shock, defined by an initial
blood loss of ≥ 750 mL and at least one clinical sign of
shock (systolic blood pressure < 100 mmHg or pulse >
100 beats per minute).
The University of California, San Francisco (UCSF)
Committee on Human Research (approval number
H6899-23524), the National Reproductive Health
Research Committee of the Nigeria Federal Ministry of
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Maternity Teaching Hospital and Assiut University
Women’s Health Center gave ethical approval for the
study. After an explanation of study aims, risks and ben-
efits, all pre-intervention study participants gave verbal
consent, and all NASG participants gave written consent
to the use of the NASG. A United States Federal waiver
of consent/authorization for minimal-risk research (45
CFR 46, 45 CFR 164.512) was obtained so that women
who were unconscious or confused at the time of study
entry were enrolled in the study without consent or
with a relative’s consent. Once the woman had regained
consciousness and attained a normal sensorium, she was
consented and gave written permission, even if a relative
had given consent on her behalf while she was
unconscious.
The evidence-based protocol for the treatment of PPH
and shock included administration of crystalloid intrave-
nous fluids (≥ 1500 mL in the first hour), uterotonic
medications (oxytocin, ergometrine, syntometrine, miso-
prostol), uterine massage for patients with uterine atony,
vaginal procedures (repair of lacerations, curettage for
retained tissue, bimanual compression and/or manual
removal of placenta) and when necessary, abdominal
surgeries (arterial ligation, B lynch compression sutures,
hysterectomy). After entry to the study, all study partici-
pants in both phases had blood loss measured with a
calibrated blood collection and measurement drape
(BRASS-V Fixable Drape™, Madurai, India), which was
placed under them for accurate measurement of blood
loss during resuscitation and hemorrhage treatment.
This drape has been compared as equivalent to spectro-
photometry for accuracy [13].
For women in the intervention phase of the study, the
NASG was applied at the time of study admission and
remained in place for the duration of the study. The
NASG was applied sequentially, starting at the ankles
with two segment #1 panels, one for each ankle, then to
the calves (segments #2), thighs (segments #3), then seg-
ment #4 to the pelvis, and finally closing the double seg-
ment (#5 and #6), with the pressure ball, around the
abdomen. All patients were monitored every 15 minutes
for vital signs, level of consciousness, uterine condition,
bleeding, and urine output, until they were stable. If sur-
gery were required for NASG patients, the abdominal
section was opened immediately before the skin incision
and closed after the abdominal bandage was applied.
Study discharge and NASG removal time were deter-
mined by two hours of hemodynamic stability (systolic
blood pressure > 100 mmHg and pulse < 100 beats per
minute) and vaginal bleeding of < 50 mL/hour. The
device was then removed in the same order as it was
applied, starting at the ankles with 15 minute intervals
between each segment.
Clinician/data collectors were trained in the standard
management of PPH and shock, collection and
Figure 1 An NASG fully applied.
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lection forms. In Nigeria, paper data forms were
reviewed by data supervisors and the Nigerian Principal
Investigators, copied, and sent to UCSF where data were
entered into a Microsoft Access database (Microsoft,
Redmond, WA, USA) and checked for errors and incon-
sistencies. In Egypt, paper forms were reviewed by the
Egyptian Principal Investigators and electronically trans-
mitted by data fax (Clinical DataFax Systems Inc.,
Ontario, Canada) to UCSF.
Aw o m a n ’s condition on study entry was calculated
using mean arterial pressure (MAP = [2*Diastolic Blood
Pressure] + Systolic Blood Pressure/3) [14]. Primary out-
comes included cumulative blood loss measured in the
drape, emergency hysterectomy, and “adverse out-
comes,” which was a combined variable of severe mater-
nal morbidity and mortality. Severe maternal morbidity
included end-organ dysfunctions related to hemorrhage
including cardiac, pulmonary, renal, and CNS [15].
Tests of significance of differences by study phase were
chi-squares for categorical variables, t-tests (assuming
unequal variances) for normally-distributed continuous
variables and Wilcoxon rank-sum tests for non-normally
distributed continuous variables. Normality was tested
using qnorm and sktest in STATA.
To estimate the independent effect of the NASG, we
used a multiple logistic regression model to control for
other characteristics which might predict adverse out-
comes. The independent variables included in the model
were selected on the basis of their prior significance in
the literature on maternal mortality and for significant
association (at the 95% confidence level) with mortality
and morbidity in bivariate analyses of this data. Vari-
ables included in the final model were high parity, MAP
< 60, where the patient began bleeding (outside the
facility and transferred in vs. began bleeding in the facil-
ity), and study phase (pre-intervention or NASG). All
data were analyzed using STATA version 10 (StataCorp,
College Station, TX, USA).
Results
A total of 854 women were included in the analysis of
which 343 were in the pre-intervention phase and 511
in the NASG phase. The demographic characteristics of
the participants in the two phases are shown in Table 1.
There were no statistically significant differences
between the pre-intervention and NASG phases with
respect to duration of pregnancy, parity, and most
hemorrhage etiologies and conditions on study entry.
Women in the pre-intervention phase were statistically
younger (28.8 vs. 29.7, p = 0.042). There were more
women with ruptured uterus in the pre-intervention,
while there were more women with lacerations in the
NASG phase. There were no differences in condition on
study entry, except that more women in the pre-inter-
v e n t i o np h a s ew e r et r a n s f e r r e di nb l e e d i n gt h a ni nt h e
NASG phase (51.4% vs. 29.1%, p < 0.001). Equal propor-
tions, approximately 36%, had more severe shock, as
measured by MAP < 60 mmHg.
During both phases, women received comparable treat-
ment as shown in Table 2, given the low-resource setting,
many women in both phases experienced delays in receiv-
ing treatment. There were no statistically significant differ-
ences between administration of treatment uterotonics for
women with a primary or secondary diagnosis of uterine
atony, receipt of blood transfusion in the first hour or
blood transfusion at any time during the study. There was
a significantly higher proportion of women who received
≥ 1500 mL of IV fluids in the first hour in the pre-inter-
vention group, but the proportion receiving fluids did not
significantly differ by the second hour.
Women in the NASG phase experienced better out-
comes as demonstrated in Table 3. Mean measured
blood loss decreased by 50% between phases. Women
experienced a median of 400 mL blood loss after study
entry in the pre-intervention and 200 mL in the NASG
phase (p < 0.0001). There was a statistically significant
decrease in the percentage of women who experienced
an emergency hysterectomy for intractable uterine
atony, 20 (9.0%) in the pre-intervention vs. 14 (4.0%) in
the NASG (RR 0.44, 95% CI 0.23-0.86). For the com-
bined outcome of severe morbidity and mortality, the
results were also significantly better in the NASG phase,
44 (12.8%) in the pre-intervention vs. 21 (4.1%) in the
NASG (RR 0.32, 95% CI 0.19-0.53). Individually, both
severe morbidity and mortality were also significantly
decreased in the NASG phase.
In the bivariate analyses (simple logistic regression)
the following variables, in addition to study phase, were
found to be significantly associated with mortality at the
95% confidence level: parity, severity of shock, and
where bleeding began (outside of facility and transferred
in vs. began bleeding in facility). Using a multiple logis-
tic regression model that included these variables, we
estimated the independent association between the
NASG intervention and the combined outcome variable
(mortality and severe morbidity). In the multiple regres-
sion model, as shown in Table 4, severity of condition
upon study admission was strongly associated with mor-
tality after controlling for other variables in the model.
Those women with MAP < 60 mmHg had 19 times the
odds of suffering the combined adverse outcomes vari-
able (adjusted odds ratio (aOR) 19.1, 95% CI 6.95-52.65,
p < 0.001). High parity and where bleeding began were
not significantly associated with mortality/morbidity in
the adjusted model. The NASG remained significantly
associated with reduced odds of adverse outcome, (aOR
0.42, 95% CI, 0.18-0.99, p = 0.046).
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condition (MAP < 60) with mortality and morbidity, we
ran a stratified analysis of the effect of MAP < 60 on out-
come by phase. In this analysis the NASG significantly
improved outcomes for those with both more and also
less severe shock. The odds of extreme adverse outcome
were 0.19 (95% CI 0.02 - 0.99) for the MAP > 60 group
and 0.27 (95% CI 0.14-0.52) for the MAP < 60 group.
The NASG was significantly associated with reductions
in adverse outcome for both groups, and there were no
statistical differences between the odds in the two groups
(data not shown).
Discussion
PPH, a life-threatening condition globally, is associated
with 25% of maternal deaths [1]. Adding the NASG to a
standardized PPH and hypovolemic shock management
protocol in tertiary facilities in Egypt and Nigeria was
associated with a significant reduction in blood loss,
emergency hysterectomy, combined mortality and severe
morbidity, and for morbidity and mortality individually,
even when controlling for severity of shock at study
entry, parity, and where the woman began bleeding.
The NASG is not therapy or treatment but it can be
used to buy time to obtain definitive treatment. Women
in the NASG phase of the study still experienced blood
loss, emergency hysterectomies, mortality, and severe
morbidities, but at a lower rate than women who did not
receive the NASG, regardless of condition on study entry
or timing of treatment given. Rapid administration of
blood, crystalloid fluids, uterotonics, and access to
anesthesia and surgery are responsible for saving the lives
of women with PPH; the NASG enables women to better
survive delays until they receive these crucial treatments.
This study is limited primarily by the non-randomized,
pre/post-intervention design, which includes the
Table 1 Demographics, diagnoses, and condition on entry to study (n = 854)
Pre-intervention
N = 343
NASG
N = 511
p value
Study Sites
Egypt (2 referral hospitals) 223 336 –
Nigeria (4 referral hospitals) 120 175 –
Demographic Characteristics
Age: Mean years of age (SD) 28.8 (6.2) 29.7 (6.1) 0.042
Median age (IQR) 29 (25-33) 30 (25-35) –
Parity: Mean parity (SD) 3.5 (3.0) 3.4 (2.6) –
Median parity (IQR) 3 (1-5) 3 (2-4) 0.802
Pregnancy duration: Mean weeks (SD) 38.2 (2.8) 38.3 (2.6) –
Median weeks (IQR) 39 (37-40) 39 (37-40) 0.814
PPH Diagnoses
€
Uterine atony 197 (57.4) 324 (63.4) 0.079
Vaginal, cervical or genital lacerations 24 (7.0) 65 (12.7) 0.007
Retained placenta or tissue 69 (20.1) 80 (15.7) 0.092
Ruptured uterus 45 (13.1) 32 (6.3) 0.001
Placenta accreta 8 (2.3) 10 (2.0) 0.809
√
Condition on Study Entry
Where hemorrhage began < 0.001
Transferred in bleeding 145 (51.4) 104 (29.1)
Began bleeding in hospital 137 (48.6) 253 (70.9)
Estimated revealed blood loss at study entry
§
Mean mL (SD) 1223.8 (509.5) 1288.7 (447.9) –
Median mL (IQR) 1000 (1000-1500) 1000 (1000-1500) 0.008
Women with MAP < 60 or non-palpable BP** 123 (35.9) 183 (35.9) 0.995
NASG = non-pneumatic anti-shock garment. Data are n (column %), mean (SD) or median (IQR). The denominator is the entire population, unless otherwise
noted.
Tests of significance of differences by study phase were chi-square for categorical variables, t-tests (assuming unequal variances) for normally-distributed
continuous variables and Wilcoxon rank-sum tests for continuous variables with non-normal distributions.
€PPH Diagnosis includes primary or secondary diagnosis of any of the following > 24 weeks with uterine atony, rupture, placenta accreta, vaginal/cervical
lacerations, retained placenta or tissue.
√ Two-side Fisher’s exact test used.
§ Data missing for 37 patients.
** MAP < 60 category includes those with non-palpable blood pressure (BP). Data missing for 1 patient.
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eligibility criteria and clinicians influence limited entry
into the study. However, there were few statistically sig-
nificant differences in demographics and condition on
study entry between the two phases and the regression
analysis was conducted to reduce the effect of differences
between the phases. Another limitation is associated with
the lack of temporal phase concurrence. The study clini-
cians’ skill levels may have improved over time, as a
result of the frequent trainings and more diligent practice
of the evidence-based protocol. However, fewer women
in the NASG received the protocol of > 1500 mL crystal-
loid IV fluid during the first hour. Further, research in
under-staffed and over-burdened hospitals in low-
resource settings could result in lack of protocol adher-
ence, for example, fewer than 70% of all women received
a blood transfusion in the crucial first hour of shock
resuscitation. It is also possible that some women who
were referred for severe hemorrhage died before reaching
the facility, so we may be underestimating the mortality
rates. The length of the pre-intervention phase was
shorter than the intervention phase in each of the four
Nigerian facilities, this partially accounts for the larger
number of women in the intervention phase; however,
there were no demographic differences or differences in
c o n d i t i o no ns t u d ye n t r yb e t w e e nw o m e ni nt h et w o
phases.
Statistical analyses were limited by the rare outcomes
of morbidity and mortality. Odds ratios may be
inflated in small studies, and it is possible that they are
inflated in this study given that adverse outcome
events were rare. Corrections to adjust for rare event
bias (e.g. alternatives to maximum likelihood estima-
tors) have been suggested in the literature, but the
slight gains in precision afforded were not preferred
due to the increased complexity of the results. Thus,
we opted for a conventional statistical test (multiple
logistic regression) that can be easily interpreted by a
wide readership.
Conclusion
The NASG may be useful in reversing shock and buying
time, thereby reducing adverse outcomes from PPH at
the referral facility level. While advances in AMTSL,
prophylaxis with uterotonics, and enhanced treatment of
uterine atony with uterotonics, including misoprostol,
are now being stressed [4,16,17], not all uterine atony
will respond to these measures. Further, uterotonics will
not address non-atonic etiologies such as lacerations or
ruptured uterus. In this study, uterine atony comprised
57.4% (pre-intervention phase) and 63.4% (NASG phase)
of all PPH etiologies, thereby excluding 40% of women
with PPH from rapid medical treatment. Balloon
Table 2 Treatments for shock and hemorrhage during
pre-intervention and NASG study phases (n = 854)
Treatment Pre-
intervention
N = 343
NASG
N = 511
p
value
Any uterotonics administered* 215 (96.9) 343
(98.0)
0.414
√
≥ 1500 mL IV fluids within 1st
hour†
275 (80.2) 363
(71.0)
0.003
≥ 1500 mL IV fluids within 2nd
hour†
300 (87.5) 453
(88.7)
0.599
Blood transfusion within 1
st hour 227 (66.2) 315
(61.5)
0.159
Blood transfusion after study
admission
318 (92.7) 474
(92.8)
0.979
NASG = non-pneumatic anti-shock garment. Data are n (column %). The
denominator is the entire population, unless otherwise noted.
*Of women with uterine atony as primary or secondary diagnosis. Data are for
572 cases.
√ Two-sided Fisher’s Exact test used.
† The protocol asked for 1500 mL to be administered in the first hour of
resuscitation; the majority of women received fluids within the first hour and
fifteen minutes.
Table 3 Outcomes during pre-intervention and NASG study phases (n = 854)
Outcome Pre-intervention
N = 343
NASG
N = 511
Relative Risk (95%CI) p
Measured vaginal blood loss in drape*:
Mean mL (SD) 424.1 (302.3) 220.5 (144.0) –
Median mL (IQR) 400 (250-500) 200 (200-210) – right< 0.0001
Emergency hysterectomy
‡ 20 (9.0) 14 (4.0) 0.44 (0.23-0.86) –
Combined Outcome: Severe morbidity** and mortality 44 (12.8) 21 (4.1) 0.32 (0.19-0.53) –
Morbidity** 13 (4.2) 5 (1.0) 0.24 (0.09-0.67) –
Mortality 31 (9.0) 16 (3.1) 0.35 (0.19-0.62) –
NASG = non-pneumatic anti-shock garment. Data are n (%) or mean (SD). The denominator is the entire population, unless otherwise noted.
* For cases in which the calibrated blood collection drape was used and there were data for blood loss. Wilcoxon rank-sum test used to compare distributions by
study phase. Data are for 784 cases.
‡ Data on emergency hysterectomy are only for women with primary or secondary diagnosis of uterine atony (n = 573).
** Includes renal failure, acute respiratory distress syndrome, heart failure, cerebral impairment (seizures, unconsciousness, motor/cognitive loss) lasting more
than 24 hours after resuscitation from shock. Denominator is the number of women who survived (n = 807).
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a treatment for uterine atony, and, as with the utero-
tonics, does not address hypovolemia [18,19]. In many
low-resource settings there is currently no treatment for
hypovolemic shock during long delays prior to obtaining
definitive treatment.
The NASG’s simple and inexpensive design makes it
an easy to use first-aid device in low-resource referral
facility settings. These findings show promise for saving
women’s lives from PPH and add to a growing NASG
literature for all etiologies of obstetric hemorrhage in
Pakistan, Mexico, Egypt and Nigeria [9-12].
New strategies and technologies are needed to reduce
the global public health epidemic of maternal mortality.
This study indicates the potential of the NASG at the
referral facility for PPH. However, many women birth at
home attended by unskilled birth attendants or family
members. Therefore, attention should be focused on
evaluation of the use of the NASG at the clinic level to
determine if earlier application, before and during trans-
port, will have a greater impact on decreasing adverse
maternal outcomes.
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number of observations in Table 4 is less than 854 because of missing data. Hospital facility was used as a control variable in the model but not shown in
Table 4.
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